Stay updated on Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial
Sign up to get notified when there's something new on the Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial page.

Latest updates to the Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial page
- Check7 days agoChange DetectedRevision updated from v3.6.0 to v3.6.2, indicating a minor platform update to the ClinicalTrials.gov interface. The change reflects an underlying update to the page rendering and features without modifying study content or user-facing information.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedNew help and navigation items were added (How to Read a Study Record, Common Questions, How to Join a Study), and the Intervention/Treatment label was added/normalized. The header now shows Last verified and Last known status was, and the page revision was bumped to v3.6.0.SummaryDifference2%

- Check29 days agoChange DetectedThe page shows a new revision label (v3.5.5) replacing the previous (v3.5.4), indicating a backend or UI update without affecting the study content.SummaryDifference0.1%

- Check50 days agoChange DetectedThe page revision was updated from v3.5.3 to v3.5.4, indicating a new release of the page template. This appears to be a maintenance update and does not alter the study details or user-facing content.SummaryDifference0.1%

- Check71 days agoChange DetectedThis updates the platform’s revision label shown at the bottom of the page from v3.5.2 to v3.5.3, reflecting a site/version change rather than any modifications to the study details.SummaryDifference0.1%

- Check78 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial page.